Targeting dysfunctional healingwith immune-modulating peptides

Controlling the interplay of inflammatory responses and the presence of microbes

 Xinnate is developing pharmaceutical therapies based on a pioneering technology of immune modulating peptides, that targets dysfunctional healing by controlling presence of microbes and the complex interplay of inflammatory responses.

Xinnate is conducting an ambitious research and clinical program for TCP-25, which includes a phase 1b clinical study in patients with Epidermolysis Bullosa (EB). Late-stage clinical development and commercialization will take place in partnership with one or more leading pharmaceutical companies.


Using the body’s natural defence to promote healing

Read more

The opportunity

Next generation cost-efficient treatment in a growing market of wounds and skin inflammation

Read more

The foundation

Proven effect based on 15 years of internationally recognized research

Read more

We transform life and the recovery process for patients facing complex skin challenges. We do this by integrating groundbreaking scientific insight about dysfunctional immune response into everyday clinical practice.

More about the concept
Meet us

Upcoming Events

We plan to attend a number of major scientific and partnering events and we are happy to meet you there

To Events

Scientific Publications

Explore our publications on endotoxic shock and sepsis models, biomaterials, mode of action, and other related publications on BioC or related variants.

To Publications